The p53 breast cancer tissue biomarker in Indian women

Breast Cancer: Targets and Therapy

Volumn 3, Issue , 2011, Pages 71-78

  Patil, Vinayak W ^a   Tayade, Mukund B ^a   Pingale, Sangeeta A ^a   Dalvi, Shubhangi M ^a   Rajekar, Rajesh B ^a   Deshmukh, Hemkant M ^a   Patil, Shital D ^a   Singhai, Rajeev ^a  

^a SIR J J GROUP OF HOSPITALS   (India)

Author keywords

Breast cancer; Cancer tissue biomarkers; Doxorubicin; Immunohistochemistry; Infiltrating duct cancer; Neoadjuvant chemotherapy; p53; Paclitaxel

Indexed keywords

EID: 84902280846     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S20695     Document Type: Article

References (26)

1. Holmes FA, Valero V, Walters RS, et al. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999;10(4): 403-411.
2. Holmes FA, Madden T, Newman RA, et al. Sequence dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996;14(10):2713-2721.
3. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 2000;13(11): 2688-2699.
4. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;(5 Suppl 6):S3-S6.
5. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res. 1999;5(7):1876-1883.
6. Anelli A, Anelli TF, Youngson B, Rosen PP, Borgen PI. Mutations of the p53 gene in male breast cancer. Cancer. 1995;75(9): 2233-2238.
7. Bonetti A, Zaninelli M, Leone R, et al. Bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 1998;4(10):2331-2336.
8. Miller CW, Aslo A, Tsay C, et al. Frequency and structure of p53 rearrangements in human osteosarcomas. Cancer Res. 1990;50(24): 7950-7954.
9. Gianni L, Capri G, Munzone E, Straneo M. Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol. 1994;21(5 Suppl 8):29-33.
10. Hortobagyi GN, Holmes FA, Theriault RL, Rahman Z, Buzdar AU. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. Semin Oncol. 1997;24(4 Suppl 1):S11-S19.
11. Hortobagyi GN, Holmes FA. Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer. Semin Oncol. 1997;24(1 Suppl 3): S4-S7.
12. Sledge GWJ, Robert N, Sparano JA, et al. Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. Semin Oncol. 1995;22(3 Suppl 6):105-108.
13. Moliterni A, Tarenzi E, Capri G, et al. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced operable breast cancer. Semin Oncol. 1997;24(5 Suppl 17): 10-14.
14. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene. 2000; 19(27):3078-3085.
15. Hamilton A, Larsimont D, Paridaens R, et al. A study of the value of p53, HER-2/neu, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer. 2000;1(3):233-240.
16. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol induction of p21 WAF1 and p53 requires c-raf-1. Cancer Res. 1995;55(20):4623-4626.
17. Debernardis D, Sire EG, De Feudis P, et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res. 1997;57(5):870-874.
18. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med. 1996;2(1):72-79.
19. Wu GS, El Diery WS. p53 and chemo sensitivity. Nature Med. 1996; 2(3):255-256.
20. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124(7):966-978.
21. Eicheler W, Zips D, Dorfler A, Grenman R, Baumann M. splicing mutations in TP53 in human squamous cell lines influences immunohistochemical detection. J Histochem Cytochem. 2002;50(2): 197-204.
22. Logullo AF, de Moura RP, Nonogaki S, Kowalski LP, Nagai MA, Simpson AJ. A proposal for the integration of immunohistochemical staining and DNA-based techniques for the determination of TP53 mutations in human carcinomas. Diagn Mol Pathol. 2000;9(1): 35-40.
23. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemistry analysis. Mod Pathol. 1998;11(2):155-168.
24. Green M, Hortobagyi GN. Neoadjuvant chemotherapy for operable breast cancer. Oncology. 2002;16(7):871-884.
25. Lara PC, Llort M, Clavo B, et al. Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiat Oncol. 2009;4:29.
26. Henriquez-Hernandez LA, Murias-Rosales A, Gonzales-Hernandez A, et al. Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer Epidemiol. 2010;34(5):634-638.